📣Zent2U is happy to announce the successful finalization of the harmonized part of the registration procedure with European authorities for Edoxaban 15mg, 30mg and 60mg film-coated tablets. National parts of the procedure have been pending in order to obtain Marketing Authorization in a number of European countries.
📈Edoxaban is indicated in prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack (TIA) as well as in treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the prevention of recurrent DVT and PE in adults.
💊Edoxaban developed by Zentiva is a generic alternative to the medication Lixiana® by Daichi Sankyo®.
We are proud and happy to provide our partners with the possibility to enhance their cardiovascular portfolio.
📧 Partner up now and connect with our team today!
thomas.koene@zentiva.com - Thomas Koene - Head of Zent2U
tomas.pilarcik@zentiva.com – Tomas Pilarcik – Head of B2B Europe
rahul.padhye@zentiva.com – Rahul Padhye – Head of B2B International
nina.fuentes@zentiva.com – Nina Fuentes de Tienda – Key Account Manager B2B Europe
yuliyana.manolova@zentiva.com - Yuliyana Manolova - Head of Distribution and Clinical Trials
ℹ️Disclaimer: Edoxaban is currently not offered or made available in countries where relevant patents are in force.
#systemicembolism #stroke #B2B #Zent2U #Zentiva
